The insulin pens market will register a CAGR of close to 9% by 2023.
The increasing focus on development of smart insulin pens for type 2 diabetes is likely to drive growth in the market. Companies are striving to grow in the market by incorporating advanced technologies into their products and services.
Growing incidence of diabetes have increased the demand for insulin pens in the market. Product recalls pose as a biggest threat to the market. Regulatory bodies and companies recalling products can impact the sales and a company's brand image.
The market appears to be concentrated and with the presence of few companies including BD and Eli Lilly, the competitive environment is quite intense. Factors such as the increasing focus on development of smart insulin pens and the incidences of diabetes, will provide considerable growth opportunities to insulin pens manufactures.
BD, Eli Lilly, Sanofi, and Novo Nordisk are some of the major companies covered in this report. With the presence of a considerable number of companies, this market appears to be concentrated.
According to the report, one of the major drivers for this market is the growing incidence of diabetes. The latest trend gaining momentum in the market is the increasing focus on development of smart insulin pens for type 2 diabetes. Further, the report states that one of the major factors hindering the increasing product recalls.
Key Topics Covered:
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: MARKET SIZING
- Market sizing 2018
- Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
PART 06: MARKET SEGMENTATION BY PRODUCT
- Comparison by product
Reusable insulin pens
- Disposable insulin pens
- Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- Key leading countries
- Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
PART 11: MARKET TRENDS
- Rising strategic partnerships to boost sales of insulin pens
- Increasing focus on smart insulin pens
- Growing presence of diabetes specialty centers
PART 12: VENDOR LANDSCAPE
- Landscape disruption
- Competitive scenario
PART 13: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Eli Lilly
- Novo Nordisk
For more information about this report visit https://www.researchandmarkets.com/research/g3r8tr/global_insulin?w=4